Institute for Cancer Research

Kjetil Taskén
Instiute head

Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded. Read more

Annual report 2019 (pdf):
Abstract (in Norwegian)
Download in single page format - double page (broad) format

Publication overview

Current news and events

Inside the head of a researcher: Cancer is a genetic disease

Vessela N. Kristensen
Vessela N. Kristensen

Last autumn Vessela Kristensen acceded the position of head of Division of Research and Development and Head of research at the Department of Medical Genetics, Clinic for Laboratory medicine, OUS.

With eagerness and ambition, she has already taken hold of what will be the main focus the next years.

- We want to make the good work within the field of medical genetics more visible and cooperate tighter across all professional environments within the hospital so that we together improve the service we offer our patients with cancer and other diseases.

In Nature:The Olweus lab reports that translational mistakes in cancer can be targets of immunotherapy

Maarja Laos (left) and Johanna Olweus
Maarja Laos (left) and Johanna Olweus

A combined research effort by scientists at the Weizmann Institute of Science in Israel and researchers at the Netherlands Cancer Institute in Amsterdam and Oslo University Hospital/University of Oslo, Norway, shows exactly how tumors can overcome hurdles that occur when starved for certain building blocks used in protein synthesis.  These results could be exploited for the development of new immunotherapies, as they unravel a completely new class of therapeutic targets that cannot be detected at the genomic (DNA) level. The study was published in Nature Dec 17.
The findings were presented in a full-page story in the major national newspaper VG on January 7th.

The Syljuåsen Lab reveals mechanisms preventing replication stress

First authors: (from left) Helga B. Landsverk, Lise E. Sandquist and Lilli T.E. Bay
First authors: (from left) Helga B. Landsverk, Lise E. Sandquist and Lilli T.E. Bay

The Syljuåsen Lab at the Department of Radiation Biology, Institute for Cancer Research reports new basic knowledge about factors underlying replication stress in cancer cells.
Replication stress can drive cancer development and may also be exploited in therapy. Understanding the molecular mechanisms underlying replication stress is therefore important. Transcription-replication conflicts are a major source of replication stress. The new findings by Landsverk et al. suggest that proper dephosphorylation of RNA polymerase 2, the main mediator of the transcription of DNA into mRNA, is needed to prevent such conflicts.

Sandvig-group with an article about uptake of nanoparticles into tumors

There is much focus upon using nanoparticles for cancer therapy, including discussions about how these particles are transported across the endothelial cell layer before being taken up by tumor cells.
Tore Skotland and Kirsten Sandvig from the "Intracellular transport" research group at the Department of Molecular Cell Biology at the Institute for Cancer Research recently discussed these issues in an article published in Nano Today (impact factor 16.9).

Anita Sveen awarded the ICR "Researcher of the Year" Prize for 2020

Anita Sveen (photo: Per M. Didriksen)
Anita Sveen (photo: Per M. Didriksen)

Anita Sveen (39) – senior researcher and project group leader at Institute for Cancer Research – was on December 16th awarded the prize Researcher-of-the-Year from the leadership at ICR for her outstanding scientific contributions. The award of 100 000 NOK is financed by the Radium Hospital Foundation (Radiumhospitalets legater) and is a personal scholarship for stimulating further excellence in research. 

Units and subpages

View all subunitsHide all subunits